Corporate Banner
Satellite Banner
Biomolecular Screening
Scientific Community
Become a Member | Sign in
Home>News>This Article

Mirna Therapeutics Presents Preclinical Data on Lead Product Candidate

Published: Thursday, January 24, 2013
Last Updated: Thursday, January 24, 2013
Bookmark and Share
Mirna Therapeutics, Inc. announced that new preclinical data from its lead product candidate will be presented this week at the Keystone conference on Non-coding RNAs in Development and Cancer.

New data will be presented on the pharmacology, pharmacokinetics and toxicology of MRX34, a liposomal formulation containing a mimic of the miR-34 tumor suppressor. miR-34 represses the expression of more than 20 oncogenes and inhibits processes required for cancer cell viability, cancer stemness, metastasis, and chemoresistance. The company has previously demonstrated that intravenous administration of the miR-34 mimic can inhibit the growth of pre-existing B-cell lymphoma, liver, lung and prostate cancer (Craig et al., 2012; Wiggins et al., 2010, Trang et al., 2011, Liu et al., 2011).

MRX34 was well tolerated in rodents and non-human primates during IND-enabling studies and did not induce RNAi-mediated toll-like receptor activation or immune response at anticipated therapeutic dose levels. The pharmacokinetic profiles suggest a satisfactory residence time in blood and will be used to determine the recommended human starting dose and treatment regimen in the clinic.

“These data continue to support the safety profile and therapeutic potential of MRX34. We are on track to file an Investigational New Drug application (IND) for MRX34 with the US Food and Drug Administration and initiate clinical testing of this miRNA replacement therapy approach in the first half of this year in patients diagnosed with primary liver cancer or advanced solid cancers with liver involvement,” said Paul Lammers, M.D., President and Chief Executive Officer of Mirna Therapeutics.

This project was funded in part by a Cancer Prevention and Research Institute of Texas (CPRIT) Commercialization grant.

Further Information
Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 2,600+ scientific posters on ePosters
  • More than 3,800+ scientific videos on LabTube
  • 35 community eNewsletters

Sign In

Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Scientific News
Enzyme Malfunction May be Why Binge Drinking Can Lead to Alcoholism
A new study in mice shows that restoring the synthesis of a key brain chemical tied to inhibiting addictive behavior may help prevent alcohol cravings following binge drinking.
Cell's Waste Disposal System Regulates Body Clock Proteins
New way to identify interacting proteins could identify potential drug targets.
Compound Doubles Up On Cancer Detection
Researchers have found that tagging a pair of markers found almost exclusively on a common brain cancer yields a cancer signal that is both more obvious and more specific to cancer.
Promising Drug Candidate to Treat Chronic Itch
In a new study, scientists from the Florida campus of The Scripps Research Institute (TSRI) describe a class of compounds with the potential to stop chronic itch without the adverse side effects normally associated with medicating the condition.
Are Changes to Current Colorectal Cancer Screening Guidelines Required?
Editorial suggests more research is needed to pinpoint age to end aggressive screening.
Assessing Cancer Patient Survival and Drug Sensitivity
RNA editing events another way to investigate biomarkers and therapy targets.
New Molecular Marker for Killer Cells
Cell marker enables prognosis about the course of infections.
Potential Target for Treatment of Autism
Grant of $2.4 million will support further research.
Sniffing Out Cancer
Scientists have been exploring new ways to “smell” signs of cancer by analyzing what’s in patients’ breath.
Inroads Against Leukaemia
Potential for halting disease in molecule isolated from sea sponges.

Skyscraper Banner
Go to LabTube
Go to eposters
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
2,600+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
3,800+ scientific videos